AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Tivic Health Receives Approval to Sell 8.44M Common Shares by Selling Shareholders
ByAinvest
Friday, Jun 6, 2025 4:45 pm ET1min read
Tivic Health has filed a prospectus to resale 8.44M shares of common stock by selling shareholders. The company will not receive any proceeds from the sale. The prospectus is not an offer to sell.
Moleculin Biotech, Inc., a biotechnology company based in Houston, Texas, has filed an amended Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC). The filing, dated June 6, 2025, includes details about the company's planned sale of up to 10,869,565 shares of common stock and up to 32,608,696 accompanying Series E warrants to purchase shares of common stock [1].The amended registration statement indicates that the company is offering the securities on a reasonable best efforts basis. The securities are expected to be issued in a single closing, and the combined public offering price per share of common stock or pre-funded warrant and accompanying common warrant will be fixed for the duration of this offering. Moleculin Biotech has engaged Roth Capital Partners, LLC as its sole placement agent for the offering [1].
The company's common stock is listed on the Nasdaq Capital Market under the symbol "MBRX." As of June 5, 2025, the last reported sale price of the common stock on Nasdaq was $0.69 per share. The actual number of securities, the combined offering price per share of common stock or pre-funded warrant and accompanying common warrant, and the exercise price per share of common stock for the accompanying common warrants will be determined based on market conditions at the time of pricing [1].
The filing also includes information about the company's corporate structure, executive officers, and legal counsel. The company's chief executive officer and chairman is Walter V. Klemp, and the company's principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, Texas 77007 [1].
References:
[1] https://quantisnow.com/insight/amendment-sec-form-s1a-filed-by-moleculin-biotech-inc-6075729
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet